Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2007 2
2008 1
2009 3
2010 6
2011 5
2012 2
2013 3
2014 5
2015 2
2016 3
2017 4
2018 11
2019 9
2020 6
Text availability
Article attribute
Article type
Publication date

Search Results

56 results
Results by year
Filters applied: . Clear all
Page 1
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.
Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson SL, Su PF, Shyr Y, Camidge DR, Sequist LV, Glisson BS, Khuri FR, Garon EB, Pao W, Rudin C, Schiller J, Haura EB, Socinski M, Shirai K, Chen H, Giaccone G, Ladanyi M, Kugler K, Minna JD, Bunn PA. Kris MG, et al. Among authors: shirai k. JAMA. 2014 May 21;311(19):1998-2006. doi: 10.1001/jama.2014.3741. JAMA. 2014. PMID: 24846037 Free PMC article. Clinical Trial.
Safety and efficacy of pembrolizumab in a patient with advanced melanoma on haemodialysis.
Chang R, Shirai K. Chang R, et al. Among authors: shirai k. BMJ Case Rep. 2016 Sep 22;2016:bcr2016216426. doi: 10.1136/bcr-2016-216426. BMJ Case Rep. 2016. PMID: 27659911 Free PMC article.
Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial.
Ferris RL, Saba NF, Gitlitz BJ, Haddad R, Sukari A, Neupane P, Morris JC, Misiukiewicz K, Bauman JE, Fenton M, Jimeno A, Adkins DR, Schneider CJ, Sacco AG, Shirai K, Bowles DW, Gibson M, Nwizu T, Gottardo R, Manjarrez KL, Dietsch GN, Bryan JK, Hershberg RM, Cohen EEW. Ferris RL, et al. Among authors: shirai k. JAMA Oncol. 2018 Nov 1;4(11):1583-1588. doi: 10.1001/jamaoncol.2018.1888. JAMA Oncol. 2018. PMID: 29931076 Free PMC article. Clinical Trial.
Clinical outcomes in non-small-cell lung cancer patients receiving concurrent metformin and immune checkpoint inhibitors.
Afzal MZ, Dragnev K, Sarwar T, Shirai K. Afzal MZ, et al. Among authors: shirai k. Lung Cancer Manag. 2019 May 7;8(2):LMT11. doi: 10.2217/lmt-2018-0016. eCollection 2019 Oct. Lung Cancer Manag. 2019. PMID: 31645894 Free PMC article.
Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients.
Pabla S, Conroy JM, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Hagen J, Giamo V, Andreas J, Lenzo FL, Yirong W, Dy GK, Yau E, Early A, Chen H, Bshara W, Madden KG, Shirai K, Dragnev K, Tafe LJ, Marin D, Zhu J, Clarke J, Labriola M, McCall S, Zhang T, Zibelman M, Ghatalia P, Araujo-Fernandez I, Singavi A, George B, MacKinnon AC, Thompson J, Singh R, Jacob R, Dressler L, Steciuk M, Binns O, Kasuganti D, Shah N, Ernstoff M, Odunsi K, Kurzrock R, Gardner M, Galluzzi L, Morrison C. Pabla S, et al. Among authors: shirai k. J Immunother Cancer. 2019 Feb 1;7(1):27. doi: 10.1186/s40425-019-0506-3. J Immunother Cancer. 2019. PMID: 30709424 Free PMC article.
Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma.
Afzal MZ, Mercado RR, Shirai K. Afzal MZ, et al. Among authors: shirai k. J Immunother Cancer. 2018 Jul 2;6(1):64. doi: 10.1186/s40425-018-0375-1. J Immunother Cancer. 2018. PMID: 29966520 Free PMC article.
Melanoma Surveillance Strategies: Different Approaches to a Shared Goal.
Shirai K, Wong SL. Shirai K, et al. Ann Surg Oncol. 2018 Mar;25(3):583-584. doi: 10.1245/s10434-017-6321-5. Epub 2018 Jan 2. Ann Surg Oncol. 2018. PMID: 29294186 No abstract available.
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors.
Conroy JM, Pabla S, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Andreas J, Giamo V, Wang Y, Lenzo FL, Bshara W, Khalil M, Dy GK, Madden KG, Shirai K, Dragnev K, Tafe LJ, Zhu J, Labriola M, Marin D, McCall SJ, Clarke J, George DJ, Zhang T, Zibelman M, Ghatalia P, Araujo-Fernandez I, de la Cruz-Merino L, Singavi A, George B, MacKinnon AC, Thompson J, Singh R, Jacob R, Kasuganti D, Shah N, Day R, Galluzzi L, Gardner M, Morrison C. Conroy JM, et al. Among authors: shirai k. J Immunother Cancer. 2019 Jan 24;7(1):18. doi: 10.1186/s40425-018-0489-5. J Immunother Cancer. 2019. PMID: 30678715 Free PMC article.
Anaplastic Lymphoma Kinase (ALK) Signaling in Lung Cancer.
Ou SI, Shirai K. Ou SI, et al. Among authors: shirai k. Adv Exp Med Biol. 2016;893:179-187. doi: 10.1007/978-3-319-24223-1_9. Adv Exp Med Biol. 2016. PMID: 26667344 Review.
An extended overall survival analysis of pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced non-squamous non-small cell lung cancer.
Afzal MZ, Dragnev KH, Shirai K. Afzal MZ, et al. Among authors: shirai k. Ann Transl Med. 2019 Mar;7(Suppl 1):S53. doi: 10.21037/atm.2019.03.09. Ann Transl Med. 2019. PMID: 31032332 Free PMC article. No abstract available.
56 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback